Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Bendamustine has a long history in treating indolent non-Hodgkin lymphoma (iNHL).
• Limited long-term data exist regarding bendamustine's efficacy and toxicity in iNHL patients.
• Understanding long-term outcomes is crucial for optimizing treatment strategies.

Purpose of the Study:

• To evaluate the long-term efficacy and toxicity of bendamustine in patients with indolent non-Hodgkin lymphoma.
• To characterize the safety profile and durable remission rates associated with bendamustine treatment.
• To provide evidence-based insights for the management of relapsed or refractory iNHL.

Main Methods:

• A retrospective review of long-term data from three clinical trials involving bendamustine treatment.
• Analysis of data from 149 patients across 21 sites, including detailed patient demographics and treatment histories.
• Assessment of event-free survival, secondary cancer development, and stem cell collection success rates.

Main Results:

• The median event-free survival was 14.1 months.
• Long-term follow-up (median 8.9 years) revealed 23 patients developed 25 secondary cancers, including 8 cases of myelodysplastic syndrome/acute myeloid leukemia.
• A subset of patients achieved durable remissions, suggesting meaningful long-term efficacy.

Conclusions:

• Bendamustine demonstrates efficacy and an acceptable safety profile for patients with relapsed or refractory indolent non-Hodgkin lymphoma.
• Long-term follow-up data provide reassurance regarding the use of bendamustine, alone or with rituximab.
• These findings support bendamustine as a valuable treatment option for specific iNHL patient populations.